Zygel, Cannabidiol Gel Now in Phase 3 Trial, Named Orphan Drug in EU
The European Commission has granted orphan drug designation to Zygel, Zynerba Pharmaceuticals’ cannabidiol (CBD) transdermal gel candidate to treat for behavioral symptoms in people with fragile X syndrome. Orphan designation is assigned to promising therapies for life-threatening, rare diseases affecting fewer than 5 in every 10,000 people in…